OA12494A - Inhibitor of monoamine uptake. - Google Patents

Inhibitor of monoamine uptake. Download PDF

Info

Publication number
OA12494A
OA12494A OA1200300215A OA1200300215A OA12494A OA 12494 A OA12494 A OA 12494A OA 1200300215 A OA1200300215 A OA 1200300215A OA 1200300215 A OA1200300215 A OA 1200300215A OA 12494 A OA12494 A OA 12494A
Authority
OA
OAPI
Prior art keywords
methyl
phenyl
oxy
compound
aminopropane
Prior art date
Application number
OA1200300215A
Other languages
English (en)
Inventor
Edward Louis Mattiuz
John Michael Sauer
William Joe Wheeler
David Taiwai Wong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12494(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of OA12494A publication Critical patent/OA12494A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
OA1200300215A 2001-03-06 2002-02-20 Inhibitor of monoamine uptake. OA12494A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06

Publications (1)

Publication Number Publication Date
OA12494A true OA12494A (en) 2006-05-24

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300215A OA12494A (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake.

Country Status (35)

Country Link
US (2) US20040082666A1 (hu)
EP (1) EP1379492B1 (hu)
JP (1) JP2004525912A (hu)
KR (1) KR20030092012A (hu)
CN (1) CN1229331C (hu)
AP (1) AP2003002855A0 (hu)
AT (2) ATE396170T1 (hu)
AU (1) AU2002245385B2 (hu)
BR (1) BR0207716A (hu)
CA (1) CA2440161A1 (hu)
CH (1) CH695982A5 (hu)
CZ (1) CZ20032380A3 (hu)
DE (1) DE60226715D1 (hu)
DK (1) DK200301267A (hu)
EA (1) EA005768B1 (hu)
EC (1) ECSP034760A (hu)
EE (1) EE200300419A (hu)
ES (2) ES2201942B2 (hu)
FI (1) FI20031191A (hu)
GB (1) GB2389851B (hu)
HR (1) HRP20030710A2 (hu)
HU (1) HUP0303341A3 (hu)
IL (1) IL157779A0 (hu)
LT (1) LT5143B (hu)
LU (1) LU91038B1 (hu)
LV (1) LV13119B (hu)
NO (1) NO20033921L (hu)
NZ (1) NZ527431A (hu)
OA (1) OA12494A (hu)
PL (1) PL363840A1 (hu)
SE (1) SE526598C2 (hu)
SK (1) SK10632003A3 (hu)
TR (1) TR200705146T1 (hu)
WO (1) WO2002070457A1 (hu)
ZA (1) ZA200306882B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070457A1 (en) * 2001-03-06 2002-09-12 Eli Lilly And Company Inhibitor of monoamine uptake
US20060241188A1 (en) * 2003-08-27 2006-10-26 Elililly And Company Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
US20070015786A1 (en) * 2003-12-12 2007-01-18 Eli Lily And Company Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
CN112930179A (zh) * 2018-10-31 2021-06-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
AU642582B2 (en) * 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
AU3219800A (en) 1999-03-29 2000-10-16 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
ES2249256T3 (es) 1999-04-09 2006-04-01 Eli Lilly And Company Procedimientos de preparacion de 3-ariloxi-3-arilpropilamidas y sus intermedios.
BR0115301A (pt) * 2000-11-15 2004-12-14 Lilly Co Eli Uso de um inibidor seletivo da recaptação de norepinefrina
WO2002070457A1 (en) * 2001-03-06 2002-09-12 Eli Lilly And Company Inhibitor of monoamine uptake

Also Published As

Publication number Publication date
DE60226715D1 (de) 2008-07-03
EA005768B1 (ru) 2005-06-30
CN1229331C (zh) 2005-11-30
ES2201942A1 (es) 2004-03-16
HRP20030710A2 (en) 2004-08-31
HUP0303341A3 (en) 2007-03-28
EP1379492B1 (en) 2008-05-21
ZA200306882B (en) 2004-12-03
WO2002070457A1 (en) 2002-09-12
GB2389851A (en) 2003-12-24
FI20031191A (fi) 2003-08-25
LU91038B1 (fr) 2003-09-11
ES2305221T3 (es) 2008-11-01
LT2003075A (en) 2004-03-25
EE200300419A (et) 2004-02-16
IL157779A0 (en) 2004-03-28
DK200301267A (da) 2003-11-06
ES2201942B2 (es) 2004-12-16
SE0302361D0 (sv) 2003-09-03
US20050209341A1 (en) 2005-09-22
KR20030092012A (ko) 2003-12-03
CH695982A5 (de) 2006-11-15
LT5143B (lt) 2004-06-25
ATE396170T1 (de) 2008-06-15
SK10632003A3 (sk) 2004-06-08
AU2002245385B2 (en) 2007-01-18
LV13119B (en) 2004-06-20
EP1379492A1 (en) 2004-01-14
CN1494526A (zh) 2004-05-05
GB0323169D0 (en) 2003-11-05
NO20033921D0 (no) 2003-09-04
US20040082666A1 (en) 2004-04-29
PL363840A1 (en) 2004-11-29
US7384983B2 (en) 2008-06-10
SE0302361L (sv) 2003-09-03
NO20033921L (no) 2003-11-05
AP2003002855A0 (en) 2003-08-20
SE526598C2 (sv) 2005-10-18
ECSP034760A (es) 2003-10-28
WO2002070457A8 (en) 2004-06-03
JP2004525912A (ja) 2004-08-26
AT414238B (de) 2006-10-15
BR0207716A (pt) 2004-03-23
CZ20032380A3 (en) 2004-03-17
EA200300978A1 (ru) 2004-02-26
NZ527431A (en) 2005-05-27
HUP0303341A2 (hu) 2004-01-28
GB2389851B (en) 2005-05-25
ATA90422002A (de) 2006-01-15
TR200705146T1 (tr) 2008-02-21
CA2440161A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
US7384983B2 (en) Inhibitor of monoamine uptake
US20070032555A1 (en) Novel aryloxyphenyl-propanamines
US20110288179A1 (en) Bimatoprost crystalline form i
US9108902B2 (en) Deuterated 2-amino-3-hydroxypropanoic acid derivatives
JP3708957B2 (ja) (−)−エゼロリン、(−)−n1−ノルエゼロリンおよび(−)−n1−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩:特異的アセチルコリンエステラーゼ阻害薬としての使用
US11905276B2 (en) Bicyclic compound that acts as CRBN protein regulator
CA3160899C (en) Spiro compound serving as erk inhibitor, and application thereof
ES2893749T3 (es) Derivados de fumagilol y polimorfos de los mismos
AU2002245385A1 (en) Inhibitor of monoamine uptake
US20090149544A1 (en) Alpha-aminoamide derivatives
WO2020247429A1 (en) Pyrrolidine compounds
CN115894456A (zh) 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途
US20110152227A1 (en) Deuterium labelled derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof
AU2007201684A1 (en) Inhibitor of monoamine uptake
US7183319B2 (en) Phenylethylamine derivatives and their use in the treatment of melanoma
US20220033376A1 (en) Estrogen receptor antagonist
US20080312318A1 (en) Deuterium-enriched escitalopram
CN115572294B (zh) 一种氘代氮杂吲哚联吡唑类化合物、药物组合物和用途
US20240122876A1 (en) Compositions and methods for the treatment of ocular disorders
US20090076060A1 (en) Deuterium-enriched temsirolimus
JPH0772168B2 (ja) グアニジノ安息香酸エステル誘導体